About Synexa

Biomarker and Bioanalysis Specialists

Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays. With a team of 150 across five global laboratory locations; Cape Town, London, Berlin, Turku (Finland) and Rockville (Maryland USA), we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, clinical bioanalysis, soluble biomarker analysis (utilising MSD, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and our ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis. We partner with our customers to contribute to the furtherment of scientific development and ultimately better management and treatment of human health.

Since, 2019, Synexa has been backed by Gilde Healthcare, a specialised healthcare investor.

 Translational studies, Biomarkers, PK, PD and ADA analysis

Synexa is an immunology focused analytical CRO specialized in translational studies (target engagement assay, receptor occupancy assay, study of MoA, functionality assay), biomarker and clinical bioanalysis (PK, PD, ADA...). We are GCLP/GLP/GMP certified with labs in Europe, US and Africa. For translational studies we have access to fresh patient samples notably in Oncology, Inflammation and Auto-immunity. Synexa has numerous in-house platforms for biomarker analysis: sequencing, dPCR, Nanostring, MSD, ELISA, Delfia, AlphaLISA, Gyrolab, RIA, Flow cytometry, Multiplex IF…

Biosimilar producers:    We have in-house validated developed assays for several biosimilars (Trastuzumab, Denosumab, Pertuzumab, Ustekinumab, Adalimumab, Eculizumab, Pegfilgrastim...) that we used in the past for Phase I to III,

3 areas where it could be particularly interesting to focus on:

• Biosimilar producers:    We have in-house validated developed assays for several biosimilars (Trastuzumab, Denosumab, Pertuzumab, Ustekinumab, Adalimumab, Eculizumab, Pegfilgrastim...) that we used in the past for Phase I to III,
• Radiopharmaceutical analysis: our lab in Finland can analyze radiopharmaceuticals and have more than 15 years of experience in this field,
• Translational studies: can be used as door opener since companies are looking for fresh patient samples which is not always easy to find.